DigitalCommons@UNMC

Title

BuOE and tBHQ Reduces Growth and Viability of Castrate-Resistant Prostate Cancer

Author

Jack McEvoy, University of Nebraska Medical Center
Elizabeth A. Kosmacek, University of Nebraska Medical CenterFollow
Arpita Chatterjee, University of Nebraska Medical CenterFollow
Molly Myers, University of Nebraska Medical CenterFollow
Ariel Moats, University of Nebraska Medical CenterFollow
Joshua McDowell, University of Nebraska Medical CenterFollow
Rebecca E. Oberley-Deegan, University of Nebraska Medical CenterFollow

Files

Presentation date

Summer 8-10-2022

Faculty Mentor

Dr. Rebecca Oberley-Deegan

Research Mentor

Dr. Rebecca Oberley-Deegan

Abstract

Prostate cancer is the second leading cause of cancer-related death in men. 10-20% of prostate cancer patients develop castration-resistant prostate cancer (CRPC) The median survival for CRPC patients is 14 months following diagnosis1. CRPC can spread to local tissues like the bladder, lymph nodes, and rectum but will also reach bone through distant metastasis. The metastasis of CRPC proves difficult for clinicians to treat. Redox active compounds can reduce growth and induce death of cancerous cells by the creation of ROS, which cannot be broken down by cancerous cells. This allows treatments like radiation and chemotherapy to be more effective in killing cancer.

Keywords

Prostate cancer, CRPC, BuOE, tBHQ

Recommended Citation

McEvoy, Jack; Kosmacek, Elizabeth A.; Chatterjee, Arpita; Myers, Molly; Moats, Ariel; McDowell, Joshua; and Oberley-Deegan, Rebecca E., "BuOE and tBHQ Reduces Growth and Viability of Castrate-Resistant Prostate Cancer" (2022). Posters: 2022 Summer Undergraduate Research Program. 7.
https://digitalcommons.unmc.edu/surp2022/7